Sign in
CompletedNo phase

Defining the Genetic Etiology of Suppurative Lung Disease in Children and Adults

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Aurora, Bethesda, Chapel Hill, Palo Alto, Seattle, and St Louis, United StatesSee the 6 sitesAlso in 1 other country, 2 sites
Trial code
Status
Completed
People taking part
436 people enrolled
Started
1 Dec 2020
Ended
6 Aug 2025
Type of study
Observational, 2 groups
Treatments tested
  • Genetic Testing for PCD or PID
  • Unaffected Family Member Genetic Testing
Record updated
21 August 2025

Who can take part

Age
5 years to 45 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • General Criteria
  • Age 5-45 years
  • Male and Female Subjects
  • All races and ethnicities; Major Clinical Criteria
  • Bronchiectasis in > 1 lobe; Minor Clinical Criteria, Lung
  • Neonatal respiratory distress (in term neonates with O2 requirement)
  • Chronic wet cough (year-round for at least 12 months)
  • Recurrent episodes of bacterial bronchitis
  • Recurrent pneumonia (confirmed on chest x-ray)
  • Respiratory non-tuberculous mycobacteria (NTM) (documented respiratory NTM culture); Minor Clinical Criteria, Other
  • Chronic nasal congestion
  • Recurrent/chronic paranasal sinusitis
  • Ongoing middle-ear disease and/or tympanostomy tube placement at age ≥ 4 years
  • Organ laterality defect
  • Low nasal nitric oxide (< 77 nL/min) (by plateau measurement)
  • Confirmed family history of PID or PCD

Who cannot take part

  • Conditions known to be commonly associated with bronchiectasis, such as prior mycobacterium tuberculosis
  • Post-lung or heart transplant, or other conditions requiring immunosuppression therapy
  • Other confounding features, such as lung disease due to prematurity (born < 28 weeks gestation) or HIV
  • Have not had standard clinical evaluation to address other potential causes of chronic oto-sino- pulmonary disease, particularly cystic fibrosis, aspiration or airway anatomic abnormalities
  • Anyone who has a confirmed genetic diagnosis of PCD or PID
  • Cystic Fibrosis
  • Alpha-antitrypsin deficiency in adults (18 years and older)
  • Congenital upper or lower airway anomalies
  • Neurological compromise and evidence of recurrent aspiration

Other criteria

  • Pediatric subjects (aged 5-17 years): Inclusion criteria include the major criterion (bronchiectasis in > 1 lobe on current or chest CT in previous 24 months, if available for review), plus one minor criterion, or two minor criteria, if bronchiectasis is not present, (including at least 1 "lung" minor criteria)
  • Adult subjects (aged 18-45 years): Inclusion criteria include the major criteria (bronchiectasis in > 1 lobe on current or chest CT in previous 36 months, if available for review), plus one minor criterion, or three minor criteria, if bronchiectasis is not present, (including at least 1 "lung" minor criteria)

Where in United States

Also in 1 other country, 2 sites

  • Children's Hospital ColoradoAurora, United States
  • National Heart Lung and Blood InstituteBethesda, United States
  • University of North Carolina at Chapel HillChapel Hill, United States
  • Stanford UniversityPalo Alto, United States
  • Seattle Children's HospitalSeattle, United States
  • Washington University in St. LouisSt Louis, United States

About the trial

What the trial wants to find out

The investigators will utilize a systematic approach for the diagnostic evaluation of patients to identify characteristics which may distinguish between Primary Immunodeficiency (PID) disorders versus Primary Ciliary Dyskinesia (PCD).

The 2 groups in the trial

  • Affected Participants

    Subjects who have suppurative lung disease without a known genetic diagnosis

    Treatment: Genetic Testing for PCD or PID

  • Unaffected Family Members

    Unaffected family members may be enrolled in the study for collection of DNA only

    Treatment: Unaffected Family Member Genetic Testing

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
21 August 2025